Cannabis and Coronavirus : What Cannabis Patients Want to Know Jennifer Grant https://www.rxleaf.com/cannabis-and-coronavirus-what-cannabis-patients-want-to-know/ February 17, 2020 There is evidence that cannabis can reduce viral load in HIV, can it help COVID-19 patients? At the time of writing, there were 69, 287 confirmed cases of the coronavirus and 1670 deaths. With the rapid escalation of the outbreak, these numbers will surely be outdated by the time of publication. With several regions heading into states of emergencies, including quarantine, nervous travelers are looking for anti viral herbs to reduce the chance of infection. Patients have asked us: What about cannabis? There have been rumors about successful treatments for coronavirus, [...]
Lire la suiteWhere Is Marijuana Legal in the US? [2020] https://www.testclear.com/Where-Is-Marijuana-Legal-in-the-US-2020.aspx Marijuana continues to tread between legal and illegal status, depending on where you are looking in the US and for what purpose you are using the substance. Where Is Marijuana Legal? Medical Marijuana Recreational Marijuana Decriminalized THC-low, CBD-High Allowed Table of Contents Where Is Marijuana Legal? Where Is Marijuana Decriminalized? What Are State Marijuana Laws? What Is the Impact of Marijuana Legalization? What Is the Cole Memorandum? Is Marijuana Legal at the Federal Level? What’s Next for the Legalization of Marijuana? Where Does the Public Stand on Marijuana? What Can You Do? As far as the [...]
Lire la suiteAbuse potential assessment of cannabidiol (CBD) in recreational polydrug users : A randomized, double-blind, controlled trial Kerri A. Schoedel, Isabella Szeto, Beatrice Setnik, Edward M. Sellers, Naama Levy-Cooperman, Catherine Mills, Tilden Etges, Kenneth Sommerville Epilepsy & Behavior, 2018, 88, 162–171. Doi : 10.1016/j.yebeh.2018.07.027 a b s t r a c t Rationale : Treatment with a highly purified oral solution of cannabidiol (CBD), derived from the plant Cannabis sativa L., demonstrated some evidence of central nervous system (CNS)-related adverse events in patients enrolled in phase 3 trials for treatment of childhood-onset epilepsy. Cannabidiol was categorized as a Schedule 1 substance by the United States Drug [...]
Lire la suiteAutorisation Temporaire Exceptionnelle d'Utilisation compassionelle du cannabis médical Laurent Appel (conseil en communication spécialisé en réduction des risques) 06.81.54.10.96 mailto : laurent.appel@asud.org relayé par www.Principesactifs.org, 26/03/2020 La chaine de soins et de médicament est en tension maximum. Le rôle de chacun est de détecter les failles actuelles et surtout futures pour éviter d'ajouter encore de la tension et faire tout sauter.Le cannabis médical peut jouer un rôle majeur tant comme solution thérapeutique alors que qon manque sera un facteur important de tensions. D'un point de vue médical, il va manquer aux patients déjà traités clandestinement et surtout au million de patients en automédication. Nous risquons donc avoir [...]
Lire la suiteIACM: Déclaration du Conseil sur la pandémie actuelle du corona virus et l'utilisation des cannabinoïdes IACM-Bulletin du 26 Mars 2020 Plusieurs études en laboratoire suggèrent que les cannabinoïdes peuvent avoir des effets antiviraux et antibactériens. Nous l’avons rapporté à plusieurs reprises dans le Bulletin de l'IACM. Cependant, il n'y a aucune preuve que des cannabinoïdes, tels que le CBD, le CBG ou le THC, ou encore des préparations de cannabis protègent contre l'infection du SRAS-CoV2 ou pourraient être utilisés pour traiter le Covid-19, la maladie produite par ce virus. Par ailleurs, rien ne prouve que l'utilisation de cannabinoïdes puisse augmenter le risque d'infection [...]
Lire la suiteA Review of Human Studies Assessing Cannabidiol’s (CBD) Therapeutic Actions and Potential C. Michael White The Journal of Clinical Pharmacology, 2019, 59, (7) 923–934 Doi : 10.1002/jcph.1387 Abstract Cannabidiol (CBD) is a highly touted product for many different disorders among the lay press. Numerous CBD products are available, ranging from a US Food and Drug Administration (FDA) approved product called Epidiolex to products created for medical marijuana dispensaries and products sold in smoke shops, convenience stores, and over the Internet.The legal status of the non–FDA approved products differs depending on the source of the CBD and the state,while the consistency and quality of the non–FDA-approved [...]
Lire la suiteIACM-Bulletin du 20 Mars 2020 IACM: 20ème Anniversaire de l'IACM IACM: Conférences IACM: Webinaires IACM: Bulletin IACM: Journaux IACM: Conseil d'administration IACM: Félicitations Un coup d'œil sur le passé IACM: 20ème Anniversaire de l'IACM Il y a 20 ans, un petit cercle de personnes a fondé l'IACM en tant qu'Association for Cannabis as Medicine, plus tard renommée Association for Cannabinoid Medicines. La 1ère conférence internationale de l'IACM sur les cannabinoïdes en médecine, qui s'est tenue à Berlin en 2001 avec l'hôpital de la Charité et l'Association médicale de Berlin, a réuni 80 participants [...]
Lire la suiteCannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches Marcel O. Bonn-Miller, Mahmoud A. ElSohly, Mallory J. E. Loflin, Suman Chandra and Ryan Vandrey International Review of Psychiatry, 2018, VOL. 30, NO. 3, 277–284 Doi : 10.1080/09540261.2018.1474730 ABSTRACT Accumulating evidence suggests that the endocannabinoid system is a promising target for the treatment of a variety of health conditions. Two paths of cannabinoid drug development have emerged. One approach is focused on developing medications that are directly derived from the cannabis plant. The other utilizes a single molecule approach whereby individual phytocannabinoids or novel cannabinoids with therapeutic potential are identified and synthesized for pharmaceutical [...]
Lire la suiteA cross-sectional examination of choice and behavior of veterans with access to free medicinal cannabis Mallory J E Loflin, Kimberly Babson, James Sottile, Sonya B Norman, Staci Gruber, and Marcel O Bonn-Miller The American Journal of Drug and Alcohol Abuse, 2019, VOL. 45, NO. 5, 506–513. Doi : 10.1080/00952990.2019.1604722 ABSTRACT Background : With a rise in public pressure to increase veteran access to medicinal cannabis, free cannabis collectives for military veterans are proliferating across the US. Objectives : The aim of the current study was to document which cannabis formulations and routes of administration are chosen by veterans with increased access to cannabis, and to determine [...]
Lire la suiteCannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users Katherine A. Belendiuk, Kimberly A. Babson, Ryan Vandrey, Marcel O. Bonn-Miller Addictive Behaviors, 2015, 50, 178–181 doi : 10.1016/j.addbeh.2015.06.032 a b s t r a c t Introduction : Individuals report using cannabis for the promotion of sleep, and the effects of cannabis on sleep may vary by cannabis species. Little research has documented preferences for particular cannabis types or cannabinoid concentrations as a function of use for sleep disturbances. Methods : 163 adults purchasing medical cannabis for a physical or mental health condition at a cannabis dispensary were recruited. They provided self-report of (a)whether [...]
Lire la suite